BLOG

Adipose-Derived Stem Cell Therapy in Japan: What to Know First

Published 2026.10.13 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are researching regenerative medicine in Japan, you have probably come across adipose-derived stem cell therapy. It is a treatment in which mesenchymal stem cells are taken from a small amount of your own fat tissue, cultured, and returned to your body by IV infusion. This article explains what the approach involves, how it is regulated in Japan, and which questions are worth preparing before you speak with a doctor at a clinic such as Grand Green Osaka Umekita Clinic in Osaka.

In short, this is a self-pay (non-insured) treatment option provided under Japanese regulation. Whether it is suitable for you, and what risks, costs, and expected benefits apply, can only be decided after a medical consultation. It is not a replacement for standard medical care.

What are adipose-derived mesenchymal stem cells?

Stem cells are cells with two defining abilities: they can replicate themselves, and they can develop into other cell types. The human body is estimated to contain around 37 trillion cells, and stem cells contribute to the ongoing renewal and repair of tissues. Their numbers and activity are generally understood to decline with age.

Mesenchymal stem cells (MSCs) are a type of somatic stem cell found in fat tissue, bone marrow, and other sources. Laboratory and clinical research has reported that MSCs can differentiate into fat, bone, and cartilage cells, and that they release anti-inflammatory substances and growth factors that may support tissue repair. Research in this field is active worldwide, and results vary by condition and study design, so findings from one study should not be generalized to every patient.

Why fat tissue is used as the cell source

MSCs can also be obtained from bone marrow, but bone marrow collection places a considerable burden on the body. Fat tissue is considered to contain a larger number of MSCs than bone marrow, and it can be collected through a small incision under local anesthesia. In this treatment, only a very small amount of fat, roughly a few rice-grain-sized pieces, is needed.

Because the cells come from your own body (autologous cells), the risk of rejection or allergic reaction is considered lower than with donor-derived cells or artificial materials. Lower does not mean absent, however, and any medical procedure can involve complications such as bleeding, infection, or discomfort at the collection site.

How the treatment process works

The process generally follows a sequence of steps. The details, timing, and number of sessions are determined by the treating physician, so the outline below is only a general guide.

Consultation and screening, where a doctor reviews your medical history and goals.
Collection of a small amount of fat tissue under local anesthesia on an outpatient basis.
Culture and expansion of the mesenchymal stem cells at a specialized facility.
Return of the cultured cells to your body by IV infusion, also on an outpatient basis.

Infused MSCs have been reported to travel through the bloodstream and gather at sites of inflammation or damage, a phenomenon often called homing. Because the cells are given by drip, the approach is described as a whole-body one. How much any individual patient may benefit remains uncertain, and responses differ from person to person.

Regulation and safety management in Japan

In Japan, regenerative medicine of this kind is provided under the Act on the Safety of Regenerative Medicine. Under this law, a clinic submits a regenerative medicine provision plan that is reviewed by a certified committee and then notified to the Ministry of Health, Labour and Welfare. Cell culture is carried out at facilities that meet legal requirements.

It is important to understand that this treatment is offered as a self-pay service, outside the national health insurance system. A legal framework is designed to support oversight, but it does not remove the need for you to understand the potential risks and side effects. Patients are encouraged to ask which provision plan covers the treatment they are being offered and to request an explanation in a language they understand.

Questions to prepare before your consultation

A well-prepared consultation helps both you and the doctor decide whether this option is appropriate. Consider bringing the following questions and records.

Which of my conditions or concerns is this treatment intended to address, and what is the evidence available for that use?
What are the possible risks and side effects, including those related to fat collection and infusion?
What are the total costs, number of sessions, and time frame, and what is not included?
How does this option relate to the standard treatments I am already receiving or could receive?
What follow-up is available after I return home, if I am traveling from overseas?

If you are living abroad, also bring your medical records, a list of current medications, and any imaging results, ideally with English translations. Tell the doctor about any past cancer, infection, blood-clotting problems, or pregnancy plans, because these may influence the medical judgment.

Consulting in Osaka as an international patient

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is easy to reach from Kansai International Airport and Shin-Osaka Station. The clinic provides an information page for international patients, so you can review the basics in English before making an inquiry. Fees, treatment content, risks, and eligibility are explained by the doctor during the consultation, and the clinic’s treatment page lists the current details.

Regenerative medicine is an evolving field. A balanced approach is to treat it as one option to discuss with your doctor, alongside established treatments, rather than as a guaranteed answer. If you would like to learn more, consider contacting the clinic to arrange a consultation and bring your questions from the list above.

Treatment flow overview

1ConsultationDoctor reviews history
2Fat collectionLocal anesthesia
3Cell cultureSpecialized facility
4IV infusionOutpatient

This figure is a conceptual summary of the article content

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›